Qiagen NV 

€40.28
59
+€0.16+0.4% Wednesday 16:32

統計

當日最高
40.28
當日最低
39.34
52週高點
49.83
52週低點
37.24
成交量
0
平均成交量
6
市值
0
本益比
-
股息殖利率
0.53%
股息
0.21

即將到來

股息

0.53%股息殖利率
Jan 26
€1.96
Jul 25
€0.21
Jul 25
€0.21
Jan 25
€1.21
10年成長
不適用
5年成長
不適用
3年成長
不適用
1年成長
-49.99%

財報

10Feb預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
0.44
0.49
0.54
0.59
預期EPS
0.53030506368
實際EPS
不適用

財務

3.2%利潤率
有盈利
2019
2020
2021
2022
2023
2024
3.69B營收
117.94M淨利

分析師評級

$41.58平均目標價
最高預估為 45.53。
來自過去6個月內的 5 則評分。這不是投資建議。
買入
60%
持有
40%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 QGE3.VI 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Show more...
執行長
Mr. Thierry Bernard
員工
5700
國家
NL
ISIN
NL0015002SN0

上市

0 Comments

分享你的想法

FAQ

Qiagen NV 今天的股價是多少?
QGE3.VI 目前價格為 €40.28 EUR,過去 24 小時上漲了 +0.4%。在圖表上更密切關注 Qiagen NV 股價表現。
Qiagen NV 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Qiagen NV 的股票以代號 QGE3.VI 進行交易。
Qiagen NV 去年的營收是多少?
Qiagen NV 去年的營收為 3.69BEUR。
Qiagen NV 去年的淨利是多少?
QGE3.VI 去年的淨收益為 117.94MEUR。
Qiagen NV 會發放股息嗎?
是的,QGE3.VI 的股息每 年度 發放一次。每股最新股息為 1.96 EUR。截至今日,股息殖利率(FWD)% 為 0.53%。
Qiagen NV 有多少名員工?
截至 April 05, 2026,公司共有 5,700 名員工。
Qiagen NV 位於哪個產業?
Qiagen NV從事於Health Care產業。
Qiagen NV 何時完成拆股?
Qiagen NV 上次拆股發生於 January 28, 2025,比例為 35:36。
Qiagen NV 的總部在哪裡?
Qiagen NV 的總部位於 NL 的 Venlo。